Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 505 shares at $7.00 ($4K) on 2014-10-14, disclosed to the SEC on 2014-10-14.
Scheduled sale ($4k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.00 | 105 | $735 | 20.8% |
| 2 | $7.00 | 400 | $3K | 79.2% |
| Total | $7.00 avg | 505 | $4K | 100% |
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |